Changes in cardiac biomarkers with bortezomib treatment in patients with advanced cardiac amyloidosis

E-ISSN： 1096-8652|90|11|E212-E213

ISSN： 0361-8609

Source： AMERICAN JOURNAL OF HEMATOLOGY, Vol.90, Iss.11, 2015-11, pp. : E212-E213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cardiac amyloidosis: the value of myocardial strain echocardiography in diagnosis and treatment

SONOGRAPHY, Vol. 2, Iss. 2, 2015-06 ,pp. : 32-38

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 97, Iss. 4, 2016-10 ,pp. : 342-347

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cardiac amyloidosis: where are we today?

JOURNAL OF INTERNAL MEDICINE, Vol. 278, Iss. 2, 2015-08 ,pp. : 126-144

John Wiley & Sons Inc

Access to resources Recommend Favorite

SMARTT use of cardiac biomarkers

Canadian Journal of Emergency Medicine, Vol. 4, Iss. 5, 2002-09 ,pp. : 331-332

Cambridge University Press

Access to resources Recommend Favorite

Cardiac Biomarkers in Haemodialysis Patients: The Prognostic Value of Amino-Terminal Pro-B-Type Natriuretic Peptide and Cardiac Troponin T

Nephron Clin Pract, Vol. 107, Iss. 3, 2007-09 ,pp. : c77-c81

Karger

Access to resources Recommend Favorite